Guard Therapeutics to present at upcoming investor conferences
Guard Therapeutics (publ) today announced that the company will present at the following investor conferences ahead of the upcoming readout of the Phase 2b POINTER study:
Guard Therapeutics (publ) today announced that the company will present at the following investor conferences ahead of the upcoming readout of the Phase 2b POINTER study:
The quarter marked a key milestone with the completion of patient recruitment for our Phase 2b POINTER study – ahead of schedule. The positive final safety review reinforces confidence in the trial, underscoring strong momentum and positioning us well for future value creation.
Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company’s ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective therapy in patients undergoing open-heart surgery.
Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial, POINTER, which is evaluating the kidney-protective effects of the drug candidate RMC-035 in connection with open-heart surgery. The company has received a favourable and unanimous recommendation from the DSMC to proceed with the study as planned, as no safety concerns have been identified.
Guard Therapeutics (publ) today announced that the design of its ongoing Phase 2b clinical trial, POINTER, will be presented at the annual congress of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) in Vienna, Austria.
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that the number of shares and votes in the Company has changed due to the recently completed Rights Issue (for further information, see the Company’s press release on April 4, 2025).
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”), (Nasdaq First North Growth Market: GUARD) announced on 10 March 2025 that the Board of Directors had resolved, by virtue of the authorization granted by the extraordinary general meeting held on 6 March 2025, on a rights issue of shares of approximately SEK 150 million (the “Rights Issue”). The subscription period ended on 3 April 2025. Guard Therapeutics hereby announces that the final result of the Rights Issue shows that 6,852,654 shares, corresponding to approximately 69.7 percent of the Rights Issue, were subscribed for with and without exercise of subscription rights. Accordingly, 1,020,099 shares, corresponding to approximately 10.4 percent of the Rights Issue, will be allotted to the guarantors, whereby the Rights Issue is subscribed to in aggregate approximately 80.0 percent. Guard Therapeutics will receive proceeds amounting to approximately SEK 120 million before deduction of costs attributable to the Rights Issue.
Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled in the Phase 2b POINTER study, which is evaluating the drug candidate RMC-035 as a kidney-protective treatment for patients undergoing open-heart surgery. This patient cohort serves as the basis for the study’s next major milestone – the second of two independent, company-blinded safety reviews. The outcome of this analysis is expected in the second quarter of 2025.
Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") (Nasdaq First North Growth Market: GUARD) publishes information document relating to the rights issue of shares of approximately SEK 150.0 million before deduction of issue costs, which was resolved by the Board of Directors on 10 March 2025, by virtue of the authorization granted by the extraordinary general meeting held on 6 March 2025 (the “Rights Issue”). Due to the Rights Issue, the Board of Directors has decided to postpone the annual general meeting to 15 May 2025.